EXPERT KNOWLEDGE
IN RARE DISEASES, CELL
AND GENE THERAPY
With decades of combined experience, we can help
you through every step of your journey taking
your orphan drug to market
IT’S IN OUR NATURE
TO CARE ABOUT YOU
We have highly experienced team members who care
deeply about the rare circumstances of the
conditions and challenges that are faced.
ROBUST AND
RIGOUR IN OUR
DELIVERABLES
Always under the microscope, we are judged
on our results, and we thrive on that, click
below to find out

Expert global consultancy specializing in access for orphan drugs, cell and gene therapy

At Partners4Access, we believe in striking an equilibrium in the orphan drug, cell and gene therapy world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.

A GLOBAL COMPANY WITH GLOBAL REACH

As a global company, we don’t just provide access services, we partner with our clients to help them achieve their PR&MA goals. A large part of that involves us supporting the right strategic and investment decisions. If you want to increase your success in launching an orphan drug at the right price and access conditions, Partners4Access are the right team for you.

Find Out More

Webinar: EU-5 has become EU-4! What happened to the UK?

Wednesday, June 23 2021 | 4pm BST (UK) / 11am (EST)

Focus on the EU5!” The geographical scope we have become used to identifying market opportunities and preparing the ground for orphan drug launches. After all, these 5 countries (France, Germany, Italy, Spain and UK) represent approximately 80% of potential healthcare spend in rare diseases in Europe and are duly prioritised by pharma companies. Now we are hearing requests for a different geographical scope when pharma is planning launches for orphan drugs and ATMPs: “Focus on the EU4” or more recently, “Focus on the EU4”. So, what has happened to the UK? 

This webinar will set out two opinions: the first for including the UK as a priority market when developing launch strategies for orphan drugs and ATMPs; the second against including the UK as a strategic priority.

More details

LATEST NEWS